Corvus Pharmaceuticals (NASDAQ:CRVS – Get Rating)‘s stock had its “overweight” rating reissued by stock analysts at Cantor Fitzgerald in a note issued to investors on Wednesday, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for Corvus Pharmaceuticals’ FY2022 earnings at ($0.69) EPS and FY2023 earnings at ($0.76) EPS.
Separately, StockNews.com started coverage on shares of Corvus Pharmaceuticals in a report on Friday, July 1st. They set a “sell” rating on the stock.
Corvus Pharmaceuticals Stock Performance
Shares of CRVS stock opened at $0.78 on Wednesday. The company has a market capitalization of $36.31 million, a P/E ratio of -0.97 and a beta of 0.90. The company’s 50 day moving average price is $0.96 and its two-hundred day moving average price is $1.17. Corvus Pharmaceuticals has a 52 week low of $0.75 and a 52 week high of $8.11.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of the business. State Street Corp raised its stake in Corvus Pharmaceuticals by 12.2% during the first quarter. State Street Corp now owns 112,603 shares of the company’s stock worth $185,000 after acquiring an additional 12,203 shares in the last quarter. Coastal Bridge Advisors LLC acquired a new position in Corvus Pharmaceuticals during the fourth quarter worth about $58,000. Hikari Power Ltd raised its stake in Corvus Pharmaceuticals by 150.3% during the first quarter. Hikari Power Ltd now owns 49,959 shares of the company’s stock worth $82,000 after acquiring an additional 30,000 shares in the last quarter. Vanguard Group Inc. raised its stake in Corvus Pharmaceuticals by 2.9% during the first quarter. Vanguard Group Inc. now owns 1,267,752 shares of the company’s stock worth $2,079,000 after acquiring an additional 36,002 shares in the last quarter. Finally, Acadian Asset Management LLC raised its stake in Corvus Pharmaceuticals by 72.6% during the first quarter. Acadian Asset Management LLC now owns 140,118 shares of the company’s stock worth $228,000 after acquiring an additional 58,952 shares in the last quarter. Institutional investors and hedge funds own 55.02% of the company’s stock.
Corvus Pharmaceuticals Company Profile
Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers.
- Get a free copy of the StockNews.com research report on Corvus Pharmaceuticals (CRVS)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase’s Earnings Say About the Return to the Office?
- Is The Golden Age Of Homebuilding Already Over?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.